BTIG Upgrades Medtronic (MDT) to Buy With $90 Target; UBS Cuts to $85

Medtronic (NYSE: MDT) drew competing analyst calls on Thursday, with BTIG upgrading the medical device maker to Buy and setting a $90 price target, while UBS maintained its Neutral rating and trimmed its own target from $90 to $85. Shares closed at $81.93 on June 4, 2026, up 5.11% on the session.

What Changed on Wall Street

• BTIG upgrade: BTIG raised its rating on Medtronic (NYSE: MDT) to Buy, citing a strong Q4 revenue beat and accelerating organic growth, according to Benzinga.
• BTIG price target: The new Buy rating carries a $90 price target, implying meaningful upside from Thursday's close.
• UBS holds Neutral: UBS analyst Priya Sachdeva maintained a Neutral rating on Medtronic, per Benzinga.
• UBS target cut: UBS lowered its price target from $90 to $85, a $5 reduction that places it below BTIG's more optimistic view.
• Diverging views: The two firms now sit on opposite sides of the consensus, with BTIG arguing the stock may be mispriced to the downside and UBS signalling a more cautious near-term outlook.

Why It Matters

BTIG's upgrade reflects a view that Wall Street has underweighted Medtronic's recent operational momentum, specifically pointing to a Q4 revenue beat and what the firm described as accelerating organic growth, according to Benzinga. That framing suggests BTIG believes the market has not fully credited the company's underlying business trajectory following its most recent quarterly results.

UBS's simultaneous target reduction to $85 introduces a counterpoint, indicating that at least one major institutional desk sees limited near-term catalysts sufficient to justify a higher valuation. The split between two prominent firms on both rating and target level reflects genuine uncertainty about how quickly Medtronic's growth initiatives — including its Hugo robotic-assisted surgery platform expansion and management of ongoing cardiovascular device recalls, as reported by Yahoo Finance — will translate into sustained financial improvement.

Wall Street View

The broader analyst community remains constructively positioned on Medtronic, with the consensus as of June 1, 2026 showing 8 Strong Buy, 13 Buy, 15 Hold, 1 Sell, and 0 Strong Sell ratings. That compares to a prior-period breakdown of 8 Strong Buy, 15 Buy, and 13 Hold, suggesting a modest shift toward the Hold camp over the past month. The BTIG upgrade moves in the opposite direction of that drift, while the UBS target cut aligns with it. With a forward P/E of 12.7x against a trailing P/E of 22.0x (TTM — may not reflect latest quarter), the valuation gap itself appears to be a central point of debate among analysts.

Investor Takeaway

The dueling analyst actions leave MDT investors weighing two credible but conflicting assessments: BTIG's conviction that recent revenue momentum is underappreciated versus UBS's more restrained view that upside is limited at current levels. With the stock sitting between the two new price targets of $85 and $90, Thursday's close at $81.93 means both firms see at least some room to the upside — the disagreement is one of degree, not direction.